GTx makes appointment
This article was originally published in Scrip
Executive Summary
GTx, a US biopharmaceutical company discovering, developing and commercialising small molecules that target hormone pathways to treat cancer, osteoporosis, bone loss and muscle loss, has appointed Dr Michael Brawer executive director of medical affairs and clinical development. Dr Brawer joins from Tokai Pharmaceuticals, where he served as chief medical officer since 2008. From 2006–07, he was interim chief medical officer at Threshold Pharmaceuticals.